Antimicrobial resistance

EW Nutrition launches phytogenic solution for respiratory support in the Philippines

Retrieved on: 
Monday, June 21, 2021

SINGAPORE, June 21, 2021 /PRNewswire/ -- EW Nutrition, an international player in the animal nutrition industry, has revealed Grippozon as its respiratory health solution in the Philippines.

Key Points: 
  • SINGAPORE, June 21, 2021 /PRNewswire/ -- EW Nutrition, an international player in the animal nutrition industry, has revealed Grippozon as its respiratory health solution in the Philippines.
  • In conjunction with the launch of Grippozon, EW Nutrition hosted a webinar for customers in the Philippines.
  • Acting preventively against respiratory risks, Grippozon can improve welfare and respiratory ease, reduce the need for antibiotics, and consequently mitigate the risk of antimicrobial resistance.
  • EW Nutrition is an international animal nutrition company that offers integrators, feed companies, and self-mixing farmers comprehensive solutions for animal gut health, feed quality, growth performance, and more.

Hologic Completes Acquisition of Mobidiag

Retrieved on: 
Thursday, June 17, 2021

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.
  • Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader, said Jan Verstreken, group president, international at Hologic.
  • Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Global Antimicrobial Therapeutics Markets 2021-2025: Focus on Antiviral, Antibacterial, Antifungal, & Antiparasitic - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021

The "Global Antimicrobial Therapeutics Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antimicrobial Therapeutics Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • This study identifies the rising awareness about microbial diseases as one of the prime reasons driving the antimicrobial therapeutics market growth during the next few years.
  • The report on antimicrobial therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • Also, the antimicrobial therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth.

IDbyDNA to Present Three Seminars at World Microbe Forum

Retrieved on: 
Wednesday, June 16, 2021

SAN FRANCISCO , June 16, 2021 /PRNewswire-PRWeb/ -- Today, IDbyDNA , the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its team's role at next week's World Microbe Forum, an online conference on cutting-edge, interdisciplinary microbial science.

Key Points: 
  • SAN FRANCISCO , June 16, 2021 /PRNewswire-PRWeb/ -- Today, IDbyDNA , the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its team's role at next week's World Microbe Forum, an online conference on cutting-edge, interdisciplinary microbial science.
  • Explify RPIP also predicts resistance to 60 antimicrobials based on over 1,200 associated AMR markers supporting molecular surveillance for antimicrobial resistance.
  • The World Microbe Forum brings together international experts who will examine, discuss and envision solutions that science can offer to solve some of the gravest concerns confronting us today.
  • IDbyDNA is driving a paradigm shift in infectious disease testing by democratizing the power of genomics to improve health and decode the unknown.

Medical Students Call for Congressional Action on AMR

Retrieved on: 
Tuesday, June 1, 2021

A group of more than 150 medical students from 22 states today called on Congress to make the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act a priority.

Key Points: 
  • A group of more than 150 medical students from 22 states today called on Congress to make the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act a priority.
  • In a letter to Members of Congress , the students share their firsthand insight into the rising threat of antimicrobial resistance (AMR) among their patients, and the alarming role AMR plays in combatting infectious diseases and preparing for future pandemics.
  • The students write : In a study of 99 patients infected with COVID-19, bacterial cultures revealed infections of difficult-to-treat superbugs, including A. baumannii, K. pneumoniae, and A. flavus.
  • AMR is a threat to all of us, and the time to prepare for it is now.

We Must Reduce the Misuse of Antibiotics

Retrieved on: 
Tuesday, June 1, 2021

BALTIMORE, Md., June 1, 2021 /PRNewswire/ --Antibiotic resistance is a global health crisis, and it's fueled by theoveruse of antibiotics in livestock.

Key Points: 
  • BALTIMORE, Md., June 1, 2021 /PRNewswire/ --Antibiotic resistance is a global health crisis, and it's fueled by theoveruse of antibiotics in livestock.
  • More than 80% of antibiotics soldin the U.S. go to farm animals.
  • Tostrengthen our food systems, we mustreduce the misuse of antibiotics.
  • WHAT: A virtual panel discussing the misuse of antibiotics.

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

Retrieved on: 
Tuesday, June 1, 2021

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application.
  • SER-155 represents a novel microbiome technology with the potential to address antibiotic-resistant bacterial bloodstream infections and further to modulate host immunomodulatory responses to decrease graft-versus-host disease.
  • Additionally, the engraftment of SER-155 bacteria (a measure of pharmacokinetics) and the efficacy of SER-155 in preventing infections and GvHD will be evaluated.
  • This milestone represents another exciting opportunity to support patients through Seres microbiome therapeutic candidates and illustrates the potential for microbiome therapeutics to change how disease is treated for immunocompromised patients, said Eric Shaff, Chief Executive Officer at Seres.

Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria

Retrieved on: 
Tuesday, June 1, 2021

The study was performed by independent, world leaders in bacterial Mechanism of Action analysis and antibiotic profiling.

Key Points: 
  • The study was performed by independent, world leaders in bacterial Mechanism of Action analysis and antibiotic profiling.
  • All conditions started with 1x108 CFU/ml E. coli cells which were then treated with R327 for the indicated period of time.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Patented lead candidate RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria including their superbug forms.

Global Hospital Acquired Infections Therapeutic Market (2021 to 2028) - Featuring Pfizer, Bayer and GlaxoSmithKline Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 28, 2021

The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study.

Key Points: 
  • The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study.
  • Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections.
  • The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.
  • The publisher segmented the hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

European $13.5 Billion Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration - Opportunity Analysis and Industry Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021

b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.

Key Points: 
  • b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.
  • In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth.\nHowever, development of antibiotic resistance, driven by misuse of antibiotics and the time taken for the regulatory approval is projected to impede the market growth.\nOn the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.\n'